Exercise alleviates cardiac remodelling in diabetic cardiomyopathy via the miR-486a-5p-Mst1 pathway

Dong Sun 1,2, Haichang Wang 1,3, Yanhui Su 4, Jie Lin 2, Mingming Zhang 1, Wanrong Man 2, Xinglong Song 2, Liang Zhang 2, Baolin Guo 2, Kaikai Hao 2, Dongdong Sun 2*

1 Department of Cardiology, Tangdu Hospital, Air Force Medical University of PLA, Xi’an 710038, P.R. China
2 Department of Cardiology, Xijing Hospital, Air Force Medical University of PLA, Xi’an 710032, P.R. China
3 Heart Hospital Xi’an International Medical Center, Xi’an 710100, P.R. China
4 Department of Comprehensive Surgery of The Second Medical Center, General Hospital of Chinese People’s Liberation Army, Beijing 100853, P.R. China

A R T I C L E  I N F O
Article type: Original article
Received: Jul 28, 2020
Accepted: Dec 22, 2020
Keywords: Apoptosis, Diabetic cardiomyopathy, Exercise, Mst1 (STK4), miR-486a-5p

A B S T R A C T
Objective(s): Physical exercise has emerged as an effective therapy to mitigate cardiac remodelling in diabetic cardiomyopathy (DCM). The results of our previous studies revealed mammalian sterile 20-like kinase 1 (Mst1) is a key regulator of the progression of DCM. However, the precise molecular mechanism of physical exercise-induced cardiac protection and its association with Mst1 inhibition remain unclear.

Materials and Methods: Wildtype and Mst1 transgenic mice were challenged with streptozotocin (STZ) to induce experimental diabetes and were divided into sedentary and exercise groups. The DCM phenotype was evaluated by echocardiography, Masson’s trichrome staining, TUNEL and immunoblotting analyses. The exercise-regulated miRNAs targeting Mst1 were predicted by bioinformatic analysis and later confirmed by RT-qPCR, immunoblotting, and dual-luciferase reporter assays. In addition, cultured neonatal mouse cardiomyocytes were subjected to simulate diabetes to elucidate the underlying mechanisms.

Results: Compared to the sedentary diabetic control, physical exercise inhibited Mst1 and alleviated cardiac remodelling in mice with DCM, as evidenced by decreases in the left ventricular end-systolic internal dimension (LVESD) and left ventricular end-diastolic internal dimension (LVEDD), increases in the left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS), attenuation of collagen deposition, and the suppression of apoptosis. Bioinformatic analysis and apoptosis assessments revealed exercise exerted protective effects against DCM through miR-486a-5p release. Moreover, luciferase reporter assays confirmed miR-486a-5p directly suppressed the expression of Mst1, thereby inhibiting the apoptosis of cardiomyocytes subjected to high glucose treatment.

Conclusion: Physical exercise inhibits cardiac remodelling in DCM, and the mechanism is associated with miR-486a-5p release-induced Mst1 inhibition.

Please cite this article as:
Sun D, Wang H, Su Y, Lin J, Zhang M, Man W, Song X, Zhang L, Guo B, Hao K, Sun D. Exercise alleviates cardiac remodelling in diabetic cardiomyopathy via the miR-486a-5p-Mst1 pathway. Iran J Basic Med Sci 2021; 24:150-159. doi: 10.22038/IJBMS.2020.50808.11564

Introduction
The prevalence of diabetes has been increasing, and the burden of diabetes should be of great concern (1, 2). Cardiovascular complications are lethal consequences of diabetes, accounting for approximately 80% of diabetes-induced deaths (2). In particular, diabetic cardiomyopathy (DCM), which shows the characteristics of impaired left ventricular diastolic and later systolic dysfunctions, cardiac hypertrophy, myocardial fibrosis and myocyte cell death, leads to a higher risk of heart failure and mortality independent of traditional risk factors such as hypertension, coronary heart disease, and valvular heart disease (3-6). With the increasing prevalence of diabetes and the effective control of the other common causes of heart failure, diabetes-related cardiomyopathy and heart failure may become increasingly prominent. Therefore, research on the pathophysiology, treatment and prevention of DCM is of increasing significance in the clinical settings.

Currently, treatments for DCM consist of glycaemic control and anti-heart failure therapies, all of which are nonspecific and have relatively unsatisfactory outcomes. A number of novel therapies, such as the use of anti-oxidants (7), dietary medium-chain fatty acids (8), phosphatidylinositol 3-kinase inhibitors (9), polyunsaturated fatty acids (10-12) and visceral adipose tissue-derived serine protease inhibitors (13) have been shown to be cardioprotective. However, some of the results of these studies need further verification, and additional studies are needed for the precise control of DCM.

Mammalian sterile 20-like kinase 1 (Mst1; also known as serine/threonine-protein kinase 4 (STK4)), the mammalian homologue Hippo in Drosophila, regulates cell proliferation, apoptosis (14) and chromatin condensation (15). Mst1 has been demonstrated to induce cardiomyocyte apoptosis and cardiac dysfunction during myocardial infarction (16, 17), contributing to...
the progression of atherosclerosis (18) and worsening angiotensin II-mediated cardiac injury (19). The results of our previous studies showed that Mst1 contributes to the development of DCM by regulating apoptosis and autophagy (20, 21), suppressing glucose metabolism (21) and impairing mitophagy (22). Thus, Mst1 plays an important role in the progression of DCM.

Physical exercise not only is effective for glycaemic control in diabetes (2, 23, 24) but also protects against DCM by suppressing pathological hypertrophy (25), fibrosis (25), and apoptosis (26) and by reducing cardiovascular risks in the diabetic heart (27), although the mechanisms underlying the exercise-mediated cardioprotective effects in DCM remain to be fully elucidated.

Therefore, exercise and Mst1 have the opposite effects on DCM, but the relationship between them is unclear. Contracting muscle-derived miRNAs (28, 29) may be responsible for the regulation of Mst1 by exercise, leading to exercise-induced cardiac protection in DCM. In the present study, we observed that exercise-mediated miR-486a-5p up-regulation correlated with the inhibition of Mst1 and protected against DCM. Our results likely shed new light on the precise control of DCM.

Materials and Methods

Animals
Six- to 8-week-old C57BL/6 male mice were obtained from the Experimental Animal Centre of the Air Force Medical University (Xi’an, China), and Mst1-transgenic (Tg-Mst1) mice in a C57BL/6 background were purchased from K&D Gene Technology (Wuhan, China). All mice were housed and monitored in the Experimental Animal Centre of the Air Force Medical University in a controlled environment at 24 °C with 45% humidity and a 12-hr light/dark cycle. The C57BL/6 mice were randomly allocated to the following groups (n=5 each) to test whether Mst1 functions as a regulator of exercise-related protective effects: (a) sedentary C57BL/6 mice (Sed), (b) exercised C57BL/6 mice (ExT), (c) C57BL/6 mice with diabetes (DM), and (d) diabetic C57BL/6 mice with exercise intervention (DM+ExT). The Tg-Mst1 and control mice were randomly allocated to the following groups (n=5 each) to test whether Mst1 functions as a regulator of exercise-related protective effects: (a) Sed, (b) DM, (c) DM+ExT, (d) sedentary Mst1-transgenic mice (Tg-Mst1), (e) diabetic Tg-Mst1 mice (Tg-Mst1+DM), and (f) diabetic Tg-Mst1 mice with exercise intervention (Tg-Mst1+DM+ExT). Subsequently, the mice underwent exercise training and streptozotocin (STZ) treatment as described in the following sections. At the endpoint of the experiments, the mice were sacrificed via 10% CO₂ inhalation and the hearts were collected for further experiments. The experimental procedures and animal care were performed in accordance with the Guide for the Care and Use of Laboratory Animals (30) and approved by the Laboratory Animal Welfare and Ethics Committee of the Air Force Medical University (No. IACUC-20180113).

Establishment of diabetic mouse models
A 5-day low-dose STZ protocol was used to obtain a higher success rate of modelling, lower toxicity (31), and greater resemblance to the clinical presentation (32). STZ was administrated by intraperitoneal injection to induce diabetes in C57BL/6 or Tg-Mst1 mice (Figure S1). STZ (Cat.: S0130; Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 0.1 mol/l citrate buffer (pH 4.5) and then injected intraperitoneally into mice at a dose of 50 mg/kg body weight per day for 5 consecutive days. One week after intraperitoneal administering the last dose of STZ, the glucose levels of the mice were detected using a Yuwell 580 glucometer (Jiangsu YUYUE Medical Equipment & Supply Co., Ltd, Nanjing, China), and the mice with a blood glucose level over 16.6 mmol/l were considered diabetic and maintained for future experiments.

Exercise protocol
The exercise groups (ExT, DM+ExT, and Tg-Mst1+DM+ExT) were subjected to treadmill exercise (BW-ZH-PT Animal Treadmill; Shanghai BioWill Co., Shanghai, China) using a modified protocol from a previous study (33). Briefly (Figure S1), the training programme consisted of adaptive and regular phases. After confirmation of the well-established diabetes model, the mice were adapted to run on the treadmill for 30 min once per day over 5 days at gradually increased speeds (8, 11, 15, 18, and 22 cm/sec, 4° slope, each step for 6 min). Subsequently, the animals were exercised regularly at a speed of 22 cm/sec for 60 mins per day, 5 days a week for 12 weeks. The basic parameters of each mouse with or without exercise training were determined and are presented in Table SI.

Cardiac function evaluation
Transthoracic M-mode echocardiography was performed to evaluate cardiac function using a high-resolution ultrasound imaging system (Vevo 2100; VisualSonics, Toronto, Ontario, Canada) as previously described (34). Following 2% isoflurane inhalation anaesthesia and the depilation of mice, the left ventricular end-systolic internal dimension (LVESD) and left ventricular end-diastolic internal dimension (LVEDD) of each mouse was measured during the systolic and diastolic phases respectively, while the left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) were calculated via computed algorithms.

Cardiac fibrosis assessment
Cardiac fibrosis was evaluated via Masson’s trichrome staining and immunoblotting. A Masson’s Trichrome Stain kit (Cat.: G1340; Solarbio, Beijing, China) was used for Masson’s trichrome staining according to the manufacturer’s instructions. The details of the Western blot analysis of fibrotic proteins are described in the Western blot assay section.

For collagen staining with Masson’s trichrome, fresh cardiac tissues were prepared as 3-µm sections after being fixed (4% paraformaldehyde at 25 °C for 24 hr), dehydrated (70, 80, 90, 95 and 100% ethanol for 1 hr each, 25 °C), cleared (xylene, 2 changes for 1 hr each, 25 °C), and paraffin embedded (paraffin wax, 2 changes, 2 hr each, 52-56 °C; solidification on frozen plates afterwards). Following dewaxing (xylene, 2 changes for 30 min each, 25 °C) and rehydration
(100, 95, 90, 80 and 70% ethanol for 5 min, 25°C), the paraffin-embedded tissue sections were stained with Weigert’s iron haematoxylin solution for 5 min. After differentiation and bluing, the tissue sections were stained in Biebrich scarlet/acid fuchsine solution for 5 min. The sections were then rinsed in phosphomolybdic/phosphotungstic acid solution followed by staining with an aniline blue solution for 5 min. After dehydration and clearing, the tissue sections were covered by coverslips and were analysed using a fluorescence microscope (DM4000; Leica Microsystems, Wetzlar, Germany). Five random fields from each section were collected, and the degree of fibrosis was quantified as the collagen volume fraction (CVF; the ratio of myocardial collagen area to total vision area) using Image-Pro Plus (Media Cybernetics Inc., Rockville, MD, USA).

Apoptosis determination

Cardiomyocyte apoptosis was determined by TUNEL and Western blotting. The TUNEL assay was performed using an In Situ Cell Death Detection kit (Cat.: 11684917910; Roche, Basel, Switzerland) according to the manufacturer’s instructions, and the details of the Western blot analysis of apoptosis markers are described in a later section.

To assess apoptosis in cardiac tissues, paraffin-embedded cardiac tissue sections were incubated in a Proteinase K working solution for 30 min at 37°C after being deparaffinized and rehydrated. To investigate apoptosis in primary neonatal mouse cardiomyocytes, cell samples were fixed with 4% paraformaldehyde for 1 hr at 25°C and then permeabilized in 0.1% Triton X-100 for 2 min at 4°C.

Subsequently, the tissue sections or cells were stained with the TUNEL reaction mixture and incubated for 60 min at 37°C under a humidified atmosphere in the dark. After being rinsed in PBS, the tissue sections or cells were counterstained with DAPI Staining Solution (Cat.: C1005; Beyotime Biotechnology, Shanghai, China). After being embedded with the antifade solution (Cat.: P0126; Beyotime Biotechnology, Shanghai, China), the samples were analysed under a fluorescence microscope (DM4000; Leica Microsystems, Wetzlar, Germany). The numbers of TUNEL-positive cells and total cells were counted within 10 random fields in each sample by a researcher who was not directly involved in the study, and the apoptosis index (TUNEL-positive cells/total cells) was determined to semiquantitatively assess apoptosis.

Cultivation of neonatal mouse cardiomyocytes

Primary neonatal mouse cardiomyocytes were harvested from 1-day-old neonatal C57BL/6 mice according to a standard protocol (35). In brief, mice were sacrificed following 10% CO₂ inhalation, and the hearts were carefully removed. After being minced into small pieces (0.5-1 mm³), the hearts were incubated with 0.25% trypsin (Cat.: C0201; Beyotime Biotechnology, Shanghai, China) at 4°C overnight. The predigested cardiac tissues were then mixed with collagenase II (Cat.: 1148090; Sigma-Aldrich, St. Louis, MO, USA) and incubated at 37°C with gentle agitation for 15 min. Subsequently cardiomyocytes were obtained following cell straining and centrifugation for 5 min at 50 x g and were plated in 10-cm culture dishes and incubated for 2 hr in an incubator for preplating. After incubating, nonadherent cardiomyocytes were transferred to 6-well culture plates containing complete DMEM (Cat.: SH30022.01; GE Life Sciences, USA) supplemented with 10% foetal bovine serum (Cat.: 900-108; GEMINI Bio-Products, Woodland, CA, USA), and 1% penicillin/streptomycin (Cat.: C0222; Beyotime Biotechnology, Shanghai, China) and were maintained in a humidified incubator at 37°C under an atmosphere with 5% CO₂. The cardiomyocytes were randomly allocated into the following groups to verify the transfection efficiency and Mst1 protein levels after mimic/inhibitor transfection: (a) negative control (Control), (b) cells with miR-486a-5p mimic transfection (miR mimic), and (c) cells with miR-486a-5p inhibitor transfection (miR inhibitor). To probe the effect of miR-486a-5p on apoptosis in vitro, cardiomyocytes were randomly assigned to the following groups: (a) negative control (Control), (b) cardiomyocytes cultured under hyperglycaemic conditions (HG), (c) control cells with miR-486a-5p mimic transfection (Control+miR mimic), (d) HG cultured cells with miR-486a-5p mimic transfection (HG+miR mimic), (e) control cells with miR-486a-5p inhibitor transfection (Control+miR inhibitor), and (f) HG cultured cells with miR-486a-5p inhibitor transfection (HG+miR inhibitor). Furthermore, the relationship between miR-486a-5p and Mst1 in cardiomyocytes was evaluated. Cells were first divided randomly into 2 groups to confirm the transfection of the Mst1 over-expressing adenovirus: (a) negative control (Control) and (b) cells with adenovirus transfection (Ad-Mst1). Then, the cells were randomly allocated into the following groups to detect whether miR-486a-5p protects cardiomyocytes by targeting Mst1: (a) negative control (Control), (b) cardiomyocytes cultured under hyperglycaemic conditions (HG), (c) control cells with miR-486a-5p mimic transfection (Control+miR mimic), (d) HG cultured cells with miR-486a-5p mimic transfection (HG+miR mimic), (e) control cells with miR-486a-5p mimic transfection (Control+miR mimic+Ad-Mst1), and (f) HG cultured cells with miR-486a-5p mimic and adenovirus transfection (HG+miR mimic+Ad-Mst1).

RNA extraction and RT-qPCR

Total RNA was isolated from cardiac tissues or cells using an RNAprep pure Tissue or Cell kit (Cat.: DP431 or DP430; Tiangen Biotech Co., Beijing, China). To assess the mRNA levels of Mst1, RNA was reverse-transcribed to cDNA using a RevertAid First Strand cDNA Synthesis kit (Cat.: K1622; Thermo Fisher Scientific, Waltham, MA, USA), and RT-qPCR was performed using a Applied Biosystems StepOnePlus Real-Time PCR system (Thermo Fisher Scientific, Waltham, MA, USA). Each 50 µl reaction contained 25 µl of 2×UltraSYBR Mixture (Cat.: CW0957; CWBIO, Beijing, China), 1 µl of primer (10 µmol/l), 2 µl of cDNA template and 21 µl of ddH₂O. The thermocycling program consisted of 40 cycles of denaturation for 10 sec at 95°C, annealing for 30 sec at 60°C, and extension for 1 min at 72°C. To evaluate the expression of miR-486a-5p, an miRcute Plus miRNA First-Strand cDNA kit (Cat.: KR211; Tiangen Biotech Co., Beijing, China) and an miRcute Plus miRNA qPCR kit (Cat.: FP411; Tiangen Biotech Co., Beijing, China).
were used for reverse transcription and RT-qPCR, respectively, following the manufacturer's instructions. Each 50 μl reaction contained 25 μl of 2×miRcute plus miRNA PreMix, 1 μl of primer (10 μmol/l), 2 μl of miRNA-derived first-strand cDNA, 4 μl of 50× ROX Reference Dye and 17 μl of ddH₂O. The thermocycling conditions were as follows: 95 °C for 15 min followed by 42 cycles of 94 °C for 20 sec and 60 °C for 34 sec.

The results were normalized to the expression of β-actin (for Mst1) or U6 (for miR-486a-5p), and the 2^ΔΔCt method was used to calculate the relative expression of target genes. The primer sequences were as follows: Mst1, forward (5'-AGGCCCTCAGTATGCTCAATATG-3') and reverse (5'-TCTTGTTCGGTACCCGAATGATA-3'); β-actin, forward (5'-GGCTGTATTCCCCCTCACATG-3') and reverse (5'-CAAGTTGATGACAATGCAATG-3'); miR-486-a-5p, forward (5'-GACTTCTGACCTACGAGCT-3') and reverse (5'-GTCAGTITTITTTTITTTITTCTC-3'); U6, forward (5'-GGGAGCTTCGAAGGGTC-3') and reverse (5'-GTGGGAGCTCCGAGGT-3').

**Western blot analysis**

The protein levels of Mst1 and apoptosis markers in cardiac tissue and cell samples were analysed via standard immunoblotting using previously described protocols (20). Briefly, cardiac tissue and cell samples were lysed with RIPA lysis buffer on ice for 1 hr after which the BCA assay was used for protein quantification. An equal amount of total protein (20 μg per sample) was separated by 12% SDS-PAGE and transferred to PVDF membranes. Then, after blocking with 10% fat-free milk, the membranes were incubated with specific primary antibodies at 4 °C overnight, which was followed by an incubation with an HRP-conjugated secondary antibody at 37 °C for 40 min. Signals were developed using Bio-Rad Clarity Western ECL Substrate (Cat.: 1705061; Bio-Rad Laboratories, Hercules, CA, USA) and visualized with a Bio-Rad ChemiDoc XRS+ imaging system (Bio-Rad Laboratories, Hercules, CA, USA). The greyscale densities of bands were quantified by using ImageJ (Version: 1.52a; National Institutes of Health, Bethesda, MD, USA). Primary antibodies against the following proteins were used: collagen I (rabbit anti-mouse polyclonal; 1:1000; Cat.: ab34710, Abcam, Cambridge, MA, USA), collagen III (rabbit anti-mouse monoclonal; 1:5000; Cat.: ab7778, Abcam, Cambridge, MA, USA), Mst1 (rabbit anti-mouse monoclonal; 1:1000; Cat.: ab232551, Abcam, Cambridge, MA, USA), cleaved-caspase 3 (rabbit anti-mouse polyclonal; 1:1000; Cat.: ab2302, Abcam, Cambridge, MA, USA), cleaved-caspase 9 (rabbit anti-mouse polyclonal; 1:1000; Cat.: #95095, CST, Danvers, MA, USA), cleaved-PARP (rabbit anti-mouse monoclonal; 1:1000; Cat.: ab32024, Abcam, Cambridge, MA, USA), and GAPDH (rabbit anti-mouse monoclonal; 1:1500; Cat.: sc-32233, Santa Cruz, Dallas, Texas, USA). In addition, a goat anti-rabbit polyclonal secondary antibody conjugated to HRP (Cat.: ZB-2301; ZSGB-Bio, Beijing, China) was used.

**Bioinformatic analyses**

TargetScanMouse 7.2 (www.targetscan.org), miRDB (mirdb.org), and TarBase V.8 (http://carolina.imis.athena-innovation.gr/diana_tools/web/index.php?r=tarbasev8%2F2index/) were used to predict miRNAs that target Mst1 with the following filters: "species: mouse" and "gene symbol: Mst1/STK4". A Venn diagram was generated to determine the overlap among the database-predicted miRNAs and those induced by exercise (29).

**Cell transfection**

The miR-486a-5p mimics, miR-486a-5p inhibitor and respective negative controls (GenePharma Co., Shanghai, China) were transfected into cells using Lipofectamine 2000 reagent (Cat.: 11668-019; Thermo Fisher Scientific, Waltham, MA, USA) following the manufacturer's instructions. In brief, primary neonatal mouse cardiomyocytes were seeded in 6-well plates at a density of 1×10⁶ per well and incubated with complexes containing 5 μl RNA and 5 μl Lipofectamine 2000 Reagent at 37 °C under an atmosphere with 5% CO₂. The medium was replaced with complete medium 6 h after transfection.

The Mst1-over-expressing adenovirus was constructed by Hanbio Technology (Shanghai, China). In brief, mouse Mst1 cDNA was PCR-amplified (primers: sequences: forward (5′-atagctagcATGGAGACCGGTGACGAGCAGCAGAACA) and reverse (atatgctagcATGGAGACCGGTGACGAGCAGCAGAACA) and restriction enzyme digested, ligated and cloned into the shuttle vector pHBAD-U6-CMV. The shuttle vector over-expressing Mst1 and the backbone vector pBHGlox(delta)E1, 3Cre were transformed into competent cells for amplification. After sequencing and identification, the plasmids were extracted and cotransfected into 293 cells for recombination. The Mst1-over-expressing adenovirus was obtained after viral packaging, collection, amplification, and purification. The adenovirus harbouring Mst1 (Ad-Mst1) and the negative control (MOI:100) were transduced into cardiomyocytes for 6 hr before complete medium replacement. Further experiments were performed within 48 hr. The relevant sequences were as follows: miR-486a-5p mimics, forward (5′-UCCUGUACUGAGCUCGCCGAG-3′) and reverse (5′-GGGGCCAGCAGACAGAGGAA-3′); and miR-486a-5p inhibitor (CUGGGGGCAUGACUGAGGAGA).

**Dual-luciferase reporter gene assay**

The length of the mouse Mst1 3′UTR is 3709 bp, and the predicted miR-486a-5p binding sites in the 3′ UTR are located between 1947 and 2160 bp. The region between 1741 and 2160 bp was PCR amplified [primers: forward (5′-TAGACCCCAGGAGCAGAGAC-3′) and reverse (5′-CAGCTTCCGGAGGCCGAGCAG-3′)] and cloned into the dual-luciferase miRNA target expression vector pmirGLO (Cat.: E1330, Promega, Madison, WI, USA). After pretreatment with the miR-486a-5p mimics or negative control, cells were transfected with the pmirGLO negative control, pmirGLO-Mst1-3′UTR-wildtype, or pmirGLO-Mst1-3′_UTR-mutant vector using Lipofectamine 2000 reagent. Forty-eight hours after transfection, the cells were analysed for firefly luciferase activity using the Dual-Glo Luciferase Reporter Assay Kit (Cat.: E2920, Promega, Madison, WI, USA) according to the manufacturer’s protocol.

**Statistical analyses**

The data are presented as the mean±SEM of triplicate
Results

Exercise alleviates cardiac remodelling in mice with DCM

Diabetes was induced in C57BL/6 or Tg-Mst1 mice via an intraperitoneal injection of STZ (Figure S1). M-mode echocardiograms showed that mice in the DM group presented worse cardiac functions than those in the Sed group (Sed) (Figure 1A-E), with the LVEF decreasing from 80.72 to 32.41%, the LVFS decreasing from 48.44 to 15.32%, the LVEDD increasing from 1.74 to 3.62 mm, and the LVESD from 3.38 to 4.77 mm.

Figure 1. Exercise alleviates cardiac remodelling in mice with DCM. (A) Representative transthoracic M-mode echocardiograms. (B-E) Measurements of LVEF, LVFS, LVESD and LVEDD (n=5). (F) Representative images of Masson’s trichrome staining showing collagen deposition. (G) Quantification of collagen volume fraction using Image-Pro Plus (n=5). (H-J) Representative immunoblots and semiquantitative analysis of collagen I and collagen III. (K) Representative immunofluorescent images of staining with DAPI (blue) and TUNEL (green). (L) Quantitative assessments of apoptotic indexes (n=5). (M-P) Representative immunoblots and semiquantitative analysis of cleaved-caspase 3, cleaved-caspase 9, and cleaved-PARP.

Exercise protects against DCM by down-regulating Mst1

To determine whether exercise correlates with Mst1 in DCM, we performed RT-qPCR and immunoblotting analyses to compare the differences in Mst1 expression among the groups. The results (Figure 2A-C) showed that Mst1 mRNA and protein levels were elevated in the DCM mouse models. Furthermore, decreased Mst1 expression (Figure 2A-C) was observed in the mice in the DM+ExT group compared to the DM control mice. As Mst1 aggravates DCM via several of the pathways mentioned above, exercise-induced cardioprotective effects in DCM may require the inhibition of Mst1 function.

Exercise-induced enhancement of miR-486a-5p and potentially down-regulating of Mst1 inhibited apoptosis in cardiomyocytes

Next, the connection between exercise and Mst1 was

Mason’s trichrome staining (Figure 1F, G) and collagen I and III immunoblotting (Figure 1H-J) revealed that collagen deposition was more common in the DM group than in the Sed group. In addition, mice in the DM group exhibited more apoptotic cells than the Sed group as determined via TUNEL assay (Figure 1K, L) and Western blot analysis (Figure 1M-P). The above mentioned pathophysiological changes indicated the generation of well-established DCM models.

A moderate-intensity exercise protocol was used to evaluate the effect of exercise on DCM in mice (Figure S1). Compared to the mice in the DM control group, the exercised diabetic mice (DM+ExT) had significantly higher LVEF and LVFS as well as lower LVESD and LVEDD, demonstrating the better cardiac function of the mice in the DM+ExT group (Figure 1A-E). In addition, the mice in the DM+ExT group showed significantly lower collagen deposition than those in the DM group (Figure 1F-J). Moreover, fewer TUNEL-positive cells were observed in the DM+ExT group than in the DM group, and cleaved-caspase 3, cleaved-caspase 9 and cleaved-PARP levels consistently exhibited a trend towards down-regulation (Figure 1K-P), showing that exercise could inhibit cardiomyocytes apoptosis. Taken together, these results confirmed the cardioprotective effects of exercise, and that exercise rehabilitated the dysfunction of diabetic hearts, attenuated collagen deposition, and alleviated the apoptosis of cardiomyocytes in DCM mice.

Exercise protects against DCM via miR-486a-5p-Mst1

During DCM can counteract the cardioprotective effect of exercise, indicating that exercise protects against DCM by down-regulating Mst1.
evaluated. Previous studies (28, 29, 36) have shown that miRNAs contribute to exercise-mediated cardiac protection, and in the present study, analysis of the intersection of these miRNAs and those that potentially target the Mst1 gene (Figure 3A) showed that miR-486a-5p may function as a link between exercise and Mst1 in mice.

The RT-qPCR results confirmed that miR-486a-5p was upregulated in the diabetic hearts of mice after exercise (DM+ExT; Figure 3B). In addition, miR-486a-5p mimics significantly attenuated apoptosis, whereas a miR-486a-5p inhibitor exacerbated apoptosis in cardiomyocytes under hyperglycaemic conditions (Figure 3D, E). These results were consistent with the observed changes in expression of apoptotic biomarkers after miRNA-486a-5p mimic or inhibitor transfection (Figure 3F-I). Thus, exercise may combat DCM by upregulating miR-486a-5p, which results in the inhibition of cardiomyocyte apoptosis.

**Exercise-induced miR-486a-5p expression has an anti-apoptotic role by suppressing Mst1 in cardiomyocytes**

Subsequently, we further assessed whether miR-
miR-486a-5p can inhibit Mst1 in cardiomyocytes. Mst1 expression was significantly decreased after miR-486a-5p mimic treatment and was increased after miR-486a-5p inhibitor transfection (Figure 4A-C). Furthermore, a dual-luciferase reporter gene assay was performed to confirm the direct inhibition of Mst1 by miR-486a-5p (Figure 4D, E). The relative luciferase activity in cells harbouring the wildtype Mst1 3’UTR reporter and previously transfected with miR-486a-5p mimics was significantly reduced compared with that in the vector control cells, whereas transfection with miR-486a-5p mimics did not affect the luciferase reporter activity of the mutant Mst1 3’UTR construct. Taken together, these results showed that Mst1 is a target gene of miR-486a-5p and that the enhancement of miR-486a-5p expression by exercise decreased the expression of Mst1 by directly binding to its 3’UTR in cardiomyocytes.

To verify that miR-486a-5p could repress Mst1 expression, we restored the expression of Mst1 in cardiomyocytes via adenovirus transfection (Figure 4F-H) and observed the effect of Mst1 up-regulation on cardiomyocyte apoptosis. The results showed that the restoration of Mst1 expression could reverse the inhibition of apoptosis mediated by miR-486a-5p mimic transfection (Figure 4I-N). Thus, the above results confirmed that miR-486a-5p has anti-apoptotic effects by suppressing Mst1 expression in cardiomyocytes.
Discussion
The results of the present study demonstrated that moderate-intensity exercise has cardioprotective effects in DCM model mice by regulating Mst1 expression. Our results suggested that Mst1 may be a key molecule mediating the cardioprotective effects of exercise on DCM, and provide a feasible target to alleviate DCM.

Figure 4. Exercise-induced miR-486a-5p expression suppresses apoptosis by targeting Mst1. (A) Relative Mst1 mRNA levels after transfection of the miR-486a-5p mimic or inhibitor, as assessed by RT-qPCR; *, #, \( P<0.05 \) vs Control. (B, C) Western blot and semiquantitative analyses of Mst1 expression; *, #, \( P<0.05 \) vs Control. (D) Predicted target of miR-486a-5p in the Mst1 3’ UTR and relevant mutations. (E) Quantification of relative luciferase activities; *, \( P<0.05 \) vs Mst1 wildtype control groups; #, \( P<0.05 \) vs Mst1 mutant groups with miR-486a-5p mimic transfection. (F-H) Mst1 upregulation in cardiomyocytes after Ad-Mst1 transfection; *, \( P<0.05 \) vs Control. (I, J) Representative TUNEL staining and quantitative analysis of apoptotic cells; *, \( P<0.05 \) vs Control; #, \( P<0.05 \) vs HG; ‡, \( P<0.05 \) vs Control+miR mimic; §, \( P<0.05 \) vs HG+miR mimic; ¶, \( P<0.05 \) vs Control+miR mimic+Ad-Mst1. (K-N) Representative immunoblots and quantification of apoptotic markers; *, \( P<0.05 \) vs Control; #, \( P<0.05 \) vs HG; ‡, \( P<0.05 \) vs Control+miR mimic; §, \( P<0.05 \) vs HG+miR mimic; ¶, \( P<0.05 \) vs Control+miR mimic+Ad-Mst1. Control, negative control; miR mimic, cardiomyocytes with miR-486a-5p mimic transfection; miR inhibitor, cardiomyocytes with miR-486a-5p inhibitor transfection; Ad-Mst1, cardiomyocytes overexpressing Mst1 adenovirus transfection; HG, cardiomyocytes cultured under hyperglycaemic conditions; Control+miR mimic, control cells with miR-486a-5p mimic transfection; HG+miR mimic, HG cultured cells with miR-486a-5p mimic transfection; Control+miR mimic+Ad-Mst1, control cells with miR-486a-5p mimic and adenovirus transfection; HG+miR mimic+Ad-Mst1, HG cultured cells with miR-486a-5p mimic and adenovirus transfection. The data are presented as the means±SEM of triplicate experiments, and Student’s t-test or ANOVA was used to assess group differences.
dysfunction and protecting against DCM.

We also observed that exercise-induced miR-486a-5p expression could suppress the apoptosis of cardiomyocytes and that miR-486a-5p could directly inhibit Mst1 in DCM. These data are consistent with those of previous studies (28, 29) in which dynamic changes in the levels of miRNAs were observed in response to exercise, and several miRNAs can inhibit a variety of pathophysiological state-induced forms of cardiomyocyte apoptosis, thereby protecting the heart from injuries. In addition, our results indicated that miR-486-5p can inhibit the apoptosis of cardiomyocytes under high glucose conditions, with concomitant down-regulation of Mst1 expression. These results are in accordance with the idea that miR-486a-5p can suppress apoptosis by influencing other growth-related genes, such as PTEN (38) and FoxO1 (39).

The relationship between exercise intensity and cardioprotection should exhibit a parabolic-like effect, as evidenced by the results of a study by Chekroud et al. who showed that exercise can reduce all-cause mortality, whereas a single-bout duration of more than 60 min may have adverse effects (40). In addition, even though some studies have shown that moderate-to-high intensity physical exercise may decrease the burden of non-communicable diseases, exercise tolerance can be impaired due to underlying diseases, making high intensity physical fitness less suitable and beneficial for populations with multiple comorbidities. Thus, a moderate-intensity exercise protocol could aid in preventing the development or delay the progression of cardiomyopathy in patients with DM, and the use of exogenous miR-486a-5p may be beneficial for patients with DCM who are intolerant to physical activities. However, this type of novel miRNA-based therapy requires further investigation.

There were several limitations to our present study. As we used the STZ-induced type 1 diabetes model in the present study, the results may not be representative of all types of diabetes. Since db/db and ob/ob mice are infertile, genetically engineered mouse models with simultaneous mutations in Mst1 and the leptin receptor are poorly accessible, while STZ-induced DCM models are widely used. Therefore, we believe that the model used in the present study is relatively feasible. Moreover, we focused on cardiac dysfunction related to diabetes, namely, hyperglycaemic damage to cardiomyocytes. The use of STZ to increase the blood glucose level of animals is a reasonable approach, and the results of such experiments were also consistent with those obtained using cells cultured under hyperglycaemic conditions. However, our results were primarily obtained from studies of mice, the heart characteristics of which are different from those of humans. In addition, some diagnostic criteria of human-like echocardiographic parameters should not be applied to mice and other species. Therefore, we used an approach that is highly specific for small animal research (41) to reduce the impact of species differences in the present study, and the results will be verified in well-designed clinical trials in the future.

**Conclusion**

The results of the present study suggest that regular exercise can alleviate cardiac remodelling during DCM by enhancing the expression of miR-486a-5p, which directly suppresses the function of the key apoptotic regulator Mst1, thereby playing a crucial role in protecting the heart. Our findings may provide a better understanding of the protective effects of exercise on the heart, and suggest a novel strategy to treat DCM.

**Acknowledgment**

This research was supported by the National Natural Science Foundation of China (grant numbers 81922008, 81670204, 81770224); National key research and development plan (grant number 2018YFA0107400) and Shaanxi innovative talent promotion plan (grant number 2018KJXX-013). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We gratefully acknowledge the invaluable cooperation of all the members of the Department of Cardiology, Tangdu and Xijing Hospitals, Air Force Medical University, Xi’an, China.

**Conflicts of Interest**

The authors have no conflicts of interest to declare.

**References**

1. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 2018; 138:271-281.
2. Organization WH. Global Report on Diabetes 2016. Available from: https://www.who.int/diabetes/publications/grd-2016/en/.
3. Kannell WB, McGee DL. Diabetes and cardiovascular risk factors: The Framingham study. Circulation 1979; 59:8-13.
4. Rubler S, Dlugash J, YuceogluYZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Ame J Cardiol 1972; 30:595-602.
5. Lundbaek K. Diabetic angiopathy: a specific vascular disease. Lancet 1954; 266:377-379.
6. Vaur L, Gueret P, Lievre M, Chabaud S, Passa P. Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 Diabetes, hypertension, cardiovascular events and ramipril) study. Diabetes Care 2003; 26:855-860.
7. Thandavarayan RA, Giridharan VV, Watanabe K, Konishi T. Diabetic cardiomyopathy and oxidative stress: role of anti-oxidants. Cardiovasc Hematol Agents Med Chem 2011; 9:225-230.
8. Airhart S, Cade WT, Jiang H, Coggan AR, Racette SB, Korenblat K, et al. A diet rich in medium-chain fatty acids improves systolic function and alters the lipidomic profile in patients with type 2 diabetes: a pilot study. J Clin Endocrinol Metab 2016; 101:504-512.
9. Maffei A, Cifelli G, Carnevale R, Iacobucci R, Pallante F, Fardella V, et al. PI3Kgamma inhibition protects against diabetic cardiomyopathy in mice. Rev Esp Cardiol (Engl Ed) 2017; 70:16-24.
10. Coelho OGL, da Silva BP, Rocha D, Lopes LL, Alfenas RCG. Polyunsaturated fatty acids and type 2 diabetes: Impact on the glycemic control mechanism. Crit Rev Food Sci Nutr 2017; 57:3614-3619.
11. Siscovick DS, Barringer TA, Fretts AM, Wu JH, Lichtenstein AH, Costello RB, et al. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical
cardiovascular disease: a science advisory from the american heart association. Circulation 2017; 135:e867-e884.
12. Ghosh S, Qi D, An D, Pulinilkunnil T, Abrahani A, Kuo KH, et al. Brief episode of STZ-induced hyperglycemia produces cardiac abnormalities in rats fed a diet rich in n-PUFA Am J Physiol Heart Circ Physiol 2004; 287:H2518-2527.
13. Ke X, Hao Y, Li B, Zou J, Li X, Wei C, et al. Vaspin prevents tumor necrosis factor-alpha-induced apoptosis in cardiomyocytes by promoting autophagy. J Cardiovasc Pharmacol 2018; 77:257-267.
14. de Souza PM, Lindsay MA. Mammalian Sterile20-like kinase 1 and the regulation of apoptosis. Biochem Soc Trans 2004; 32:485-488.
15. Ura S, Masuyama N, Graves JD, Gotoh Y. Caspase deactivation of MST1 promotes nuclear translocation and chromatin condensation. Proceedings of the National Academy of Sciences of the United States of America 2001; 98:10148-10153.
16. Odashima M, Usui S, Takagi H, Hong C, Liu J, Yokota M, et al. Inhibition of endogenous Mt1 prevents apoptosis and cardiac dysfunction without affecting cardiac hypertrophy after myocardial infarction. Circ Res 2007; 100:1344-1352.
17. Wang X, Song Q. Mt1 regulates post-infarction cardiac injury through the JNK-Drp1-mitochondrial fission pathway. Cell Mol Biol Lett 2018; 23:21-42.
18. Wang T, Zhang L, Hu J, Duan Y, Zhang M, Lin J, et al. Mt1 participates in the atherosclerosis progression through macrophage autophagy inhibition and macrophage apoptosis enhancement. J Mol Cell Cardiol 2016; 98:108-116.
19. Cheng Z, Zhang M, Hu J, Lin J, Feng X, Wang S, et al. Mt1 knockout enhances cardiomyocyte autophagic flux to alleviate angiotensin II-induced cardiac injury independent of angiotensin II receptors. J Mol Cell Cardiol 2018; 125:117-128.
20. Zhang M, Zhang L, Hu J, Lin J, Wang T, Duan Y, et al. Mt1 coordinates regulates autophagy and apoptosis in diabetic cardiomyopathy in mice. Diabetologia 2016; 59:2435-2447.
21. Hu J, Wang S, Xiong Z, Cheng Z, Yang Z, Lin J, et al. Exosomal Mt1 transfer from cardiac microvascular endothelial cells to cardiomyocytes deteriorates diabetic cardiomyopathy. Biochim Biophys Acta Mol Basis Dis 2018; 1864:3639-3649.
22. Wang S, Zhao Z, Fan Y, Zhang M, Feng X, Lin J, et al. Mt1 inhibits Sirt3 expression and contributes to diabetic cardiomyopathy through inhibiting Parkin-dependent mitophagy. Biochim Biophys Acta Mol Basis Dis 2019; 1865:1905-1914.
23. Riddell MC, Gallen IW, Smart CE, Taplin CE, Adolfsson P, Lumb J, et al. Exercise management in type 1 diabetes: A consensus statement. Lancet Diabetes Endocrinol 2017;5:377-390.
24. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006; 368:1673-1679.
25. Novoa U, Arauna D, Moran M, Nunez M, Zaggmutt S, Salvidia S, et al. High-intensity exercise reduces cardiac fibrosis and hypertrophy but does not restore the nitroso-redox imbalance in diabetic cardiomyopathy. Oxid Med Cell Longev 2017; 2017:921363.
26. Kanter M, Aksu F, Takir M, Kostek O, Kanter B, Oymagil A. Effects of low intensity exercise against apoptosis and oxidative stress in streptozotocin-induced diabetic rat heart. Exp Clin Endocrinol Diabetes 2017; 125:583-591.
27. Tanasescu M, Leitzmann MF, Rimm EB, Hu FB. Physical activity in relation to cardiovascular disease and total mortality among men with type 2 diabetes. Circulation 2003; 107:2435-2439.
28. Lew JK, Pearson JT, Schwenke DO, Katare R. Exercise mediated protection of diabetic heart through modulation of microRNA mediated molecular pathways. Cardiovasc Diabetol 2017; 16:10-30.
29. Hou Z, Qin X, Hu Y, Zhang X, Li G, Wu J, et al. Longterm exercise-derived exosomal miR-342-5p. Circ Res 2019; 124:1386-1400.
30. National Research Council Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Washington (DC): National Academies Press (US) National Academy of Sciences; 2011.
31. Tang Y, Lei X, Jian W, Yan J, Wu Z, Zhao T. [Optimization of streptozotocin dosing for establishing tumor-bearing diabetic mouse models]. Nan Fang Yi Ke Da Xue Xue Bao 2019;34:827-831.
32. Damasceno DC, Netto AO, Lessi IL, Gallego FQ, Corvinho SB, Dallauqa B, et al. Streptozotocin-induced diabetes models: pathophysiological mechanisms and fetal outcomes. Biomed Res Int 2014; 2014:819065.
33. Pons S, Martin V, Portal L, Zini R, Morin D, Berdeaux A, et al. Regular treadmill exercise restores cardioprotective signaling pathways in obese mice independently from improvement in associated co-morbidities. J Mol Cell Cardiol 2013; 54:82-89.
34. Wang D, Luo P, Wang Y, Li W, Wang C, Sun D, et al. Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/protein kinase A-dependent mechanism. Diabetes 2013; 62:1697-1708.
35. Ehler E, Moore-Morris T, Lange S. Isolation and culture of neonatal mouse cardiomyocytes. J Vis Exp 2013;79:50154.
36. Russell AP, Lamon S. Exercise, skeletal muscle and circulating microRNAs. Prog Mol Biol Transl Sci 2015; 124:1386-1400.
37. Parim B, Sathibabu Uddandrao VV, Saravanan G. Diabetic cardiomyopathy: molecular mechanisms, detrimental effects of conventional treatment, and beneficial effects of natural therapy. Heart Fail Rev 2019; 24:279-299.
38. Sun XH, Wang X, Zhang Y, Hui J. Exosomes of bone-marrow stromal cells inhibit cardiomyocyte apoptosis under ischemic and hypoxic conditions via miR-486-5p targeting the PTEN/Pi3K/AKT signaling pathway. Thromb Res 2019; 177:23-32.
39. Chai X, Si H, Song J, Chong Y, Wang J, Zhao G. miR-486-5p inhibits inflammatory response, matrix degradation and apoptosis of nucleus pulposus cells through directly targeting foxo1 in intervertebral disc degeneration. Cell Physiol Biochem 2018; 48:498-508.
40. Chekroud SR, Gueorguieva R, Zheutlin AB, Paulus M, Krumholz HM, Krystal JH, et al. Association between physical exercise and mental health in 1.2 million individuals in the United States of America 2011 and 2015: a cross-sectional study. Lancet Psychiatry 2018; 5:739-746.
41. VisualSonics. Vevo® 2100 Imaging System. Available from: https://www.visualsonics.com/product/imaging-systems/vevo-2100.